Speakers - Sachs Associates
Speakers - Sachs Associates
Speakers - Sachs Associates
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
CONTACTS<br />
Piers Morgan<br />
Chief Financial Officer<br />
Aicha Diba<br />
Legal Affairs<br />
Marsha Lemmers<br />
Administrative Assistant<br />
ADDRESS<br />
Meibergdreef 61<br />
1105 BA Amsterdam<br />
The Netherlands<br />
TELEPHONE<br />
+31 (0) 20 5667509<br />
Aicha Diba<br />
+31 (0) 20 5668014<br />
Marsha Lemmers<br />
+31 (0) 20 5662402<br />
FAX<br />
+31 (0) 20 5667509<br />
EMAIL<br />
p.morgan@uniqure.com<br />
a.diba@uniqure.com<br />
m.lemmers@uniqure.com<br />
YEAR FOUNDED<br />
04.05.2012<br />
uniQure<br />
www.uniqure.com<br />
FINANCIAL SUMMARY<br />
Amounts in € x 1,000<br />
31.12.2011* 31.12.2010*<br />
Total other income 2,192 1,448<br />
Total operating costs (19,038) (20,517)<br />
Operating result (17,300) (19,069)<br />
Result for year (17,300) (19,118)<br />
Cash 3,100* 17,859<br />
*Adjusted pro forma<br />
COMPANY PROFILE<br />
uniQure is a world leader in the research and early development of human gene based therapies. uniQure<br />
has a product pipeline of several gene therapies in development: hemophilia B, acute intermittent porphyria,<br />
Parkinson’s disease and Sanfilippo. uniQure is located on the premises of the Academic Medical Center,<br />
University of Amsterdam, employs a staff with extensive scientific and industry experience, is the world leader for<br />
manufacturing of AAV-based products on a commercial scale, meeting cGMP requirements, and has extensive<br />
experience in the regulatory processes for gene therapies.<br />
MANAGEMENT<br />
Joern Aldag, CEO<br />
Carlos Camozzi, CMO<br />
Piers Morgan, CFO<br />
Harald Petry, VP, R&D<br />
Hans Preusting, VP, Bus Dev<br />
Piers Morgan, CFO<br />
Mr. Morgan joined AMT in December 2009 as Chief Financial Officer. He has over ten years experience as CFO with<br />
biotechnology companies, including Phytopharm plc, BioAlliance Pharma SA, and Arrow Therapeutics Ltd. Prior to this period,<br />
he gained ten years experience in investment banking, working in Mergers & Acquisitions, and Equity Capital Markets with<br />
Close Brothers and Ernst & Young Corporate Finance. Currently he is Non-executive Chairman of Trino Therapeutics Ltd. He<br />
qualified as a Chartered Accountant in London with PricewaterhouseCoopers<br />
t back :: next u<br />
WELCOME PHARMA LICENSING GROUPS<br />
SPEAKERS<br />
PRESENTING COMPANIES SUPPORTING ORGANISATIONS<br />
ORGANISERS
Change language